Phase III EXTEND trial shows Pixuvri (Cell Therapeutics) offers effective salvage therapy for Non-Hodgkin's Lymphoma
Results from sub-set analyses of data from the Phase III EXTEND (PIX301) clinical trial of Pixuvri (pixantrone), from Cell Therapeutics, in patients with relapsed or refractory aggressive B-cell Non-Hodgkin Lymphoma (NHL) showed efficacy in 3rd and 4th line salvage setting with and without prior Rituximab treatment. Single agent Pixuvri resulted in 30% of patients who had previously received rituximab achieving a complete or unconfirmed durable complete response lasting on average 9.5 months with 67% of patients surviving at 2 years, versus 5.6% of patients in the comparator arm who achieved an unconfirmed complete response.
In addition, the drug demonstrated superior complete response rates and progression-free survival in all the subgroups analyzed (5.4 vs. 2.8 months). The analyses were presented by Professor Ruth Pettengell, M.D., St. George's Hospital, University of London, at the 18th Congress of the European Hematology Association.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins